Our monthly Discussion Groups are hosted by a panel of leading industry experts who explore some of the key issues facing the immuno industry today.
Register below to receive a live stream of the discussion as well a complimentary report outlining the key findings and conclusions covered.
Taking place Wednesday 01 June 2022 | 15:00 BST (10:00 EDT)
Discussion Topics:
Discussion Leaders:
Taking place 14 June 2022 | 15:00 BST (10:00 EDT)
Discussion Topics:
Discussion Leaders:
Michael Zaiac, Head of Medical Affairs Oncology Region Europe, Novartis
Paul Rennert, Acting CEO, CSO, Aletabio
Taking place 23 September 2022
Viewer registration coming soon.
Taking place 24 October 2022
Viewer registration coming soon.
Taking place 28 November 2022
Viewer registration coming soon.
Reports and write-ups pertaining to previous Discussion Groups are available in our In-Depth section.
Ten-minute Introduction from our discussion group leaders:
Discussion Topics:
Discussion Leader:
April 2022
Discussion Leaders:
March 2022
Discussion Leaders:
February 2022
Discussion Topics:
Discussion Group Leaders:
October 2021
Join us for a one hour discussion on understanding the tumour microenvironment with advanced technologies. Our live event aims to bring together key opinion leaders discussing cutting-edge research into the area: from markers through to state of the art technologies to understanding immune response through to cell types of interests in tumour indications, do not miss out on attending the session to stay at the forefront of research.
Panel Discussion: Peripheral Markers To Help Understand The Tumour Microenvironment
Moderator: Paul Jones, Biomarkers Lead, UCB
Panellists:
John Rossi, Senior Vice President and Head of Translational Medicine, Cero Therapeutics
Siddha Kasar, Clinical Translational Lead of Cell Therapies, Takeda
We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.